Ignite Creation Date:
2025-12-25 @ 1:18 AM
Ignite Modification Date:
2026-01-04 @ 5:25 PM
Study NCT ID:
NCT04331093
Status:
RECRUITING
Last Update Posted:
2021-05-26
First Post:
2020-03-31
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma
Sponsor:
Di Wu
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-03-01
Start Date Type:
ACTUAL
Primary Completion Date:
2024-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12
Completion Date Type:
ESTIMATED
First Submit Date:
2020-03-31
First Submit QC Date:
None
Study First Post Date:
2020-04-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-05-24
Last Update Post Date:
2021-05-26
Last Update Post Date Type:
ACTUAL